RARE focus

RARE commitment

RARE passion

We are proud to announce that as of October 5, 2021, Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc are subsidiaries of Xeris Biopharma Holdings, Inc. Click here for more information.
Click here for more information on the SEC Documents Incorporated by Reference

Focused on Bridging Treatment Gaps

At Strongbridge Biopharma, our focus on rare diseases has resulted in a portfolio of innovative treatments for rare neuromuscular and endocrine conditions, including the commercialization of KEVEYIS in the U.S.

See our rare portfolio

Committed to Positive Results

At Strongbridge Biopharma, we are committed to delivering better results for patients, healthcare providers, employees, and investors.

Learn more about the Strongbridge difference

Passionate About Impact

The Strongbridge team is passionate about making a positive difference in the lives of patients with rare diseases. It’s why we’re here.

Meet the Strongbridge leadership team